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Abstract
Background: Wnt signaling is important in development and can also contribute to the initiation and progression of cancer.
The Secreted Frizzled Related Proteins (SFRPs) constitute a family of Wnt modulators, crucial for controlling Wnt signaling.
Here we investigate the expression and role of SFRP3 in melanoma.
Methodology/Principal Findings: We show that SFRP3 mRNA is down-regulated in malignant melanoma tumors as
compared to normal/benign tissue. Furthermore, we found that SFRP3 expression was lost in the malignant melanoma cell
lines, A2058, HTB63 and A375, but not in the non-transformed melanocyte cell line, Hermes 3A. Methylated CpG rich areas
were detected in the SFRP3 gene in melanoma cell lines and their SFRP3 expression could be restored using the
demethylating agent, 59aza-deoxycytidine. Addition of recombinant SFRP3 to melanoma cells had no effect on viable cell
numbers, but decreased cell migration and invasion. Wnt5a signaling has been shown to increase the migration and
invasion of malignant melanoma cells, and high expression of Wnt5a in melanoma tumors has been connected to a poor
prognosis. We found that recombinant SFRP3 could inhibit Wnt5a signaling, and that it inhibited melanoma cell migration
and invasion in a Wnt5a-dependent manner.
Conclusion/Significance: We conclude that SFRP3 functions as a melanoma migration and invasion suppressor by
interfering with Wnt5a signaling.
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Introduction
Wnt signaling is essential in many different biological processes
during development and tissue maintenance. Tight homeostatic
control of Wnt signaling is crucial for the organism, as aberrant
Wnt signaling can lead to developmental defects and plays
important roles in many cancers [1]. The Frizzled proteins are a
family of G-protein coupled receptors considered to be the
principal receptors for Wnt proteins. However, there are also other
putative Wnt receptors such as Ror2 [2,3]. All Wnt-ligands and
most of their cognate receptors contain a cysteine-rich domain
(CRD), through which their binding is thought to be mediated.
Activation of Wnt signaling by proteins such as Wnt3a and Wnt1
activates canonical signaling that leads to inhibition of b-catenin
proteolytic degradation. This results in b-catenin accumulation
and subsequent transcription of b-catenin-dependent promoters
via interaction with transcription factors such as TCF/Lef. In
contrast, non-canonical Wnt signaling activated for example by
Wnt5a and Wnt11, inhibits the transcriptional activation of b-
catenin but also triggers calcium signaling and JNK activation
[4,5].
Control of Wnt signaling is executed by a variety of different
modulators including the Dickkopf proteins, the Wnt Inhibitory
Factor-1 and LRP5/6 Wnt co-receptors [1]. Wnt signaling is also
regulated via the family of Secreted Frizzled-Related Proteins
(SFRPs). There are five human SFRPs and all contain a CRD
homologous to the Frizzled CRD, which binds to Wnt ligands [6].
SFRP proteins can inhibit activation of both canonical and non-
canonical Wnt signaling [7]. All SFRP members also share a
conserved Netrin domain in common with tissue inhibitor of
matrix metalloproteinases and Netrin-1 [8]. SFRPs are down-
regulated in several cancers and this is often correlated with poor
prognosis, as has been shown for breast, colorectal, and a number
of other cancers [9].
Wnt signaling affects malignant melanoma progression [1,4,10].
Malignant melanoma comprises about 4% of skin cancers and
80% of skin cancer deaths are related to malignant melanoma due
to its highly metastatic behavior. Once melanoma has spread there
are currently few effective treatment options, thus there is a great
need for a better understanding of melanoma progression [11].
Wnt signaling is crucial for cell fate determination of melanocytes
from neural crest progenitor cells, and is connected to malignant
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signaling leads to differentiation and decreased proliferation of
melanoma cells, and non-canonical signaling antagonizes this
effect [13]. Non-canonical signaling also increases the migration
and metastatic potential of melanoma cells [14,15]. Increased
expression of Wnt5a in malignant melanoma tumors is correlated
with poor prognosis [16]. Conversely, canonical signaling leads to
better prognosis in melanoma patients [13]. Currently the role of
Wnt modulators in melanoma is poorly characterized.
Here, we show reduced SFRP3 expression in malignant
melanoma tissues and cell lines compared to normal cells. We
demonstrate that this down-regulation is related to methylation of
the SFRP3 gene. Addition of SFRP3 to melanoma cells had no
effect on the number of viable cells, but decreased migration and
invasion in a Wnt5a-dependent manner. This work suggests that
SFRP3 functions as a migration and invasion suppressor in
malignant melanoma.
Results
SFRP3 mRNA is reduced in melanoma
The expression levels of SFRP3 mRNA were analyzed using
two microarray datasets, GDS1375 [17] and GDS1989 [18], from
the NCBI Gene Expression Omnibus database [19] (Figure 1A
and B). The samples were categorized as two groups, normal skin
or benign nevi (normal/benign) and melanoma. In both datasets,
there was a statistically significant difference between the normal/
benign and the melanoma groups. To further investigate SFRP3
expression in melanoma we used one non-transformed immortal-
ized human melanocyte cell line, Hermes 3A [20], and three
human melanoma cell lines, A375, A2058 and HTB63. We
analyzed SFRP3 mRNA levels using reverse transcriptase-
quantitative PCR (RT-QPCR) and SFRP3 protein levels using
an ELISA kit and immunofluorescence (Figure 1C, 1D, 1E and
S1). Low expression of SFRP3 mRNA was detected in the three
melanoma cell lines in contrast to the higher expression in the
melanocytes (Figure 1C). The same was true at the protein level;
the ELISA kit detected higher SFRP3 levels in the melanocyte
media than in the melanoma cell media (Figure 1D). The same
pattern was also observed when the intracellular SFRP3 protein
levels were analyzed and quantified by immunofluorescence
(Figure 1E and S1 respectively). The fact that we detect higher
SFRP3 protein levels in media from melanocytes than in media
from melanoma cells indicates that SFRP3 can exert its function as
a secreted Wnt modulator to a greater extent in melanocytes than
in melanoma cells.
Methylation of SFRP3 in melanoma cell lines
We hypothesized that methylation might be the cause of SFRP3
down-regulation in malignant melanoma tissue and cell lines. To
analyze possible methylation of the SFRP3 gene, the gene
sequence and promoter region of SFRP3 [21,22] were analyzed
for CpG rich areas and one was found in the first exon (Figure 2A).
This region was analyzed using methylation specific PCR in
Hermes 3A melanocytes and the malignant melanoma cell lines
A375, A2058 and HTB63. Methylated DNA was not present in
Hermes 3A cells. However, methylated DNA was present in all
three melanoma cell lines, using universally unmethylated and
methylated DNA as controls, suggesting that the methylation
could be a cancer specific event (Figure 2B). In melanoma cells
that had been treated with 59aza-deoxycytidine (59AZA) there was
a decrease in methylated DNA (Figure 2B). This data indicates
that in malignant melanoma cells, there are methylated CpG sites
in the SFRP3 gene that can be demethylated, whereas in
melanocytes no methylated CpG sites could be detected. To
investigate whether this methylation had a functional effect on
expression of SFRP3, we used RT-QPCR and immunofluores-
cence. Upon treatment with 59AZA, expression of SFRP3 mRNA
did not increase in the melanocytes but there was an increase in all
the melanoma cell lines (Figure 2C). We also detected increased
SFRP3 protein levels in the melanoma cell lines after demethyl-
ation treatment (Figures 2D, 2E and S2). In HTB63 cells, the
increase in SFRP3 protein level was detected in media but not
intracellularly. These data suggest that the SFRP3 gene is
methylated in malignant melanoma cells but not in melanocytes
and that expression and secretion of SFRP3 can be restored in
malignant melanoma cells following demethylation.
Recombinant SFRP3 decreases migration and invasion of
melanoma cells
As Wnt signaling plays a role in melanoma progression [4], we
investigated the effects of SFRP3 on proliferation/survival,
migration and invasion. There was no effect of recombinant (r)
SFRP3 on viable cell numbers, suggesting that SFRP3 does not
affect melanoma cell proliferation or survival (Figure S3). We next
investigated the effects of rSFRP3 on migration and invasion. The
effect of rSFRP3 on invasion of A2058 cells was analyzed using a
3D Matrigel invasion assay. A2058 cells treated with 1 mg/ml
rSFRP3 or carrier (0.1% BSA in PBS) were allowed to invade for
24 h. There was a statistically significant decrease in the number
of invaded cells when treated with rSFRP3 as compared to carrier-
treated cells (Figure 3A).
To investigate the effects on migration more directly, we
performed wound healing assays where A2058 cells were grown to
confluency and treated with carrier or rSFRP3 after which
scratches were made in the monolayer. Images were taken of the
scratches after 0, 16, 24 and 48 h and the scratch area was
analyzed at each time point. rSFRP3 treatment significantly
decreased the migration of A2058 cells (Figure 3B). To further
analyze the effects of SFRP3 on melanoma cell migration, time-
lapse microscopy was used. A2058 cells were treated with 1 mg/ml
rSFRP3 or carrier and the speed of migration was tracked
manually. Cell migration speed was decreased with rSFRP3
treatment over a 12-hour period (Figure 3C). Taken together our
data show that, in malignant melanoma cells, treatment with
rSFRP3 has an inhibitory effect on cell migration and invasion.
In order to investigate possible mechanisms behind the decrease
in migration and invasion induced by SFRP3 in A2058 cells, we
investigated the expression of Wnt5a in these cells since Wnt5a is
the only Wnt protein seen to increase migration and invasion of
melanoma cells [15]. We detected significantly more Wnt5a
protein in HTB63 cells compared to A2058 cells, in accordance
with previous findings [23]. The upper band most likely represents
glycosylated Wnt5a, which is the secreted and functional form of
this protein (Figure 3D). Consequently, Wnt5a is expressed in
small amounts in the A2058 cells and therefore SFRP3 treatment
could be assumed to have a limited effect on Wnt5a-dependent
functions.
SFRP3 inhibits migration in melanoma cells by
antagonizing Wnt5a
SFRP proteins have been shown to bind to and inhibit the
effects of different members of the Wnt family with various
outcomes depending on cellular/tissue context [24]. Since Wnt5a
increases migration and invasion of melanoma cells [15] and
SFRP3 and Wnt5a have previously been shown to antagonize
each other [25,26], we hypothesized that one possible mechanism
SFRP3 and Wnt5a-Dependent Melanoma Cell Migration
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invasion could be inhibition of Wnt5a signaling. To investigate
this, we utilized the Topflash luciferase reporter assay which
measures activation of canonical Wnt signaling and its subsequent
inhibition by the non-canonical signaling pathway [27,28].
rSFRP3 did not activate b-catenin mediated transcription by
itself, nor did it have an inhibitory effect on canonical signaling
activated by rWnt3a, but rWnt5a could inhibit the signaling
activated by rWnt3a in A2058 cells. When rSFRP3 was added to
cells treated with rWnt3a and rWnt5a the inhibitory effect of
Wnt5a on Wnt3a signaling was antagonized (Figure 4A).
As the Wnt/Ca
2+ pathway has been found to be important for
the invasive capacities of Wnt5a in melanoma cells [23], we
analyzed the effect of SFRP3 on Wnt5a induced intracellular
calcium signaling. A2058 cells were serum starved and pre-treated
with carrier or rSFRP3 for 24 h before measuring intracellular
Ca
2+ signaling induced by rWnt5a. In carrier pre-treated cells
Wnt5a induced a prominent increase in intracellular Ca
2+
signaling, a signal that was inhibited by more than 50% in cells
that were pre-treated with rSFRP3 (Figure 4B and 4C).
We next investigated if inhibition of Wnt5a signaling by SFRP3
was also the mechanism of the inhibition of migration observed by
stimulation of melanoma cells with rSFRP3. Wnt5a expression
was down-regulated in A2058 cells using siRNA. siRNA
transfected cells were treated with either carrier or 1 mg/ml
rSFRP3 and differences in migration were traced manually using
time-lapse microscopy. In cells transfected with scrambled siRNA
there was a decrease in migration upon rSFRP3 treatment.
Interestingly, there was no decrease in migration after treatment
with SFRP3 in cells where Wnt5a had been knocked down,
suggesting that SFRP3 inhibits migration in melanoma cells via
inhibition of Wnt5a (Figure 5A). The knock-down of Wnt5a was
validated on the RNA and protein level by RT-QPCR and
western blot, respectively (Figure S4 and 5B). In order to further
validate if SFRP3 could inhibit migration induced by Wnt5a,
A2058 cells were pre-treated with rSFRP3 or carrier in serum free
media for 24 h after which rWnt5a was added. rWnt5a increased
the migration of A2058 cells and this increase was inhibited in cells
pre-treated with rSFRP3 (Figure 5C).
To complement this finding, we investigated the effects of
SFRP3 in the melanoma HTB63 cells which have a higher Wnt5a
expression compared to A2058 cells (Figure 3D). However, we saw
no effect of 1 mg/ml of rSFRP3 on migration of these cells (data
not shown), which could be due to too low a concentration of
SFRP3 to have an inhibitory effect on migration of cells with a
high endogenous expression level of Wnt5a. To overcome this
problem we used conditioned medium from HTB63 cells
transfected with a SFRP3 vector (CM-SFRP3, expression
validated in Figure S5) or an empty vector (CM-EV) in order to
investigate the effect of SFRP3 in HTB63 cells. In migration
experiments using time-lapse microscopy there was a pronounced
and statistically significant decrease in migration of cells treated
with CM-SFRP3 compared to cells treated with CM-EV for 12 h
(Figure 5D). The large decrease of HTB63 cell migration upon
CM-SFRP3 treatment is in agreement with the high level of
Wnt5a in these cells. Consequently these data are in line with the
previous assumption that SFRP3 inhibits migration in melanoma
cells by inhibiting Wnt5a signaling.
Discussion
The present finding, that mRNA expression levels are lower in
malignant melanoma tissue than in normal skin/benign nevi is in
agreement with our observation that the SFRP3 gene is
methylated in melanoma cell lines but not in the Hermes 3A
melanocyte cell line. SFRP3 down-regulation has been demon-
strated in other cancers [29,30,31,32,33], and it was speculated
that the cause for SFRP3 down-regulation could be loss of
heterozygosity in the SFRP3 loci, 2q31-33 [30,31]. However, in
parallel it was found that the other members of the SFRP family
(SFRP1, -2, -4 and -5) were methylated in different types of cancer,
such as breast and colorectal cancer [34,35]. One of these studies
reports no methylation of the SFRP3 gene and presumably
because of this, many subsequent studies of SFRPs in cancer have
not investigated SFRP3 methylation. However, McRonald et al.
detected down-regulation of SFRP3 mRNA due to methylation in
a global methylation analysis of renal cell carcinoma patient
material. Furthermore, Kongkham et al. has detected methylation
of SFRP3 in medulloblastoma, and Marsit et al. reported increased
methylation of the SFRP3 gene in invasive bladder cancer
compared to non-invasive cancer [29,32,33]. Taken together with
previous reports on the methylation of SFRP3 in other cancers,
our data suggests that gene methylation is a major reason for the
down-regulation of SFRP3 in malignant melanoma.
Wnt5a signaling has been demonstrated to affect motility of
melanoma whereas SFRP3 has been shown to reduce growth and
motility in other types of cancer [4,36,37]. Therefore, we
speculated that down-regulation of SFRP3 might affect the
Wnt5a-driven aggressiveness of melanoma. We detected a
decrease in migration and invasion in A2058 cells upon SFRP3
treatment. Since Wnt5a increases migration and invasion of
melanoma cells [15], these findings supported our idea that
inhibition of Wnt5a signaling could be the mechanism by which
SFRP3 decreased the migration and invasion of A2058 cells.
SFRP3 could inhibit Wnt5a signaling but did not induce canonical
signaling nor did it inhibit canonical signaling induced by Wnt3a.
SFRP3 could also inhibit Wnt5a induced intracellular Ca
2+
signaling, a functional molecular read-out of Wnt5a signaling. In
A2058 cells in which Wnt5a had been down-regulated by siRNA,
the inhibitory effect on migration of SFRP3 was lost. Also, when
Wnt5a was added to A2058 cells, migration was increased and
SFRP3 was found to be able to inhibit this effect. In HTB63 cells
that express a higher level of Wnt5a, conditioned media from
SFRP3 over-expressing cells caused a large decrease in migration.
Our assumption that SFRP3-mediated inhibition of Wnt5a is the
mechanism by which it affects melanoma cell migration, readily
explains the relatively small effect of SFRP3 on migration and
invasion in A2058 cells with low expression of Wnt5a.
Figure 1. SFRP3 mRNA and protein levels are reduced in melanoma. A, Microarray data from Gene Expression Omnibus (GEO) dataset
GDS1375, Normal/benign vs. Melanoma. B, Microarray data from GEO dataset GDS1989, Normal/benign vs. Melanoma. Bars represent the 95th and
5
th percentile. C, Basal SFRP3 mRNA expression in cell lines. A human non-transformed immortalized melanocyte cell line, Hermes 3A, and three
malignant melanoma cell lines: A375, A2058 and HTB63 cells were analyzed for their SFRP3 mRNA expression using RT-QPCR. The data is
representative of 3 independent experiments and the error bars represent standard deviation (SD) within one experiment. D, Basal SFRP3 protein
levels in media from the indicated cell lines. The SFRP3 protein levels were normalized against total protein content. Error bars represent Standard
Error of the Mean (SEM) (n=4). Statistical analysis determined the following p-values; Hermes 3A vs. A375 p=0,0025, Hermes 3A vs. A2058 p=0,0051
and Hermes 3A vs HTB63 p=0,1091. E, Basal SFRP3 protein expression in cell lines. Melanocytes and melanoma cells were analyzed for SFRP3
expression using immunofluorescence. Representative immunofluorescence images from 3 independent experiments. *=p,0.05, ****=p,0.0001.
doi:10.1371/journal.pone.0018674.g001
SFRP3 and Wnt5a-Dependent Melanoma Cell Migration
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18674SFRP3 and Wnt5a-Dependent Melanoma Cell Migration
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18674The inhibitory effect of SFRPs can occur either by their ability
to bind Wnt receptors and induce signaling on their own or by
inhibiting Wnt signaling through binding Wnt proteins or their
receptors. The first option is for several reasons unlikely in the
present context. First, SFRP3 alone did not induce canonical
signaling in the Topflash assay. Secondly, SFRP3 had no effect by
itself on migration in Wnt5a-depleted cells. We therefore conclude
that the effects of SFRP3 on melanoma cell migration are due to
impaired Wnt5a signaling, either via binding between the CRD of
SFRPs to the CRD of the Wnt protein or its receptors, in
accordance with previous findings in other systems [38,39,40].
The notion that SFRP3 affects melanoma cell migration via
modulation of Wnt5a signaling is supported by numerous studies
on how Wnt5a regulates melanoma cell migration. For example,
Wnt5a can mediate migration via PKC activation, by inducing an
epithelial to mesenchymal transition (EMT), by inhibiting
metastasis suppressors such as matrix metalloproteases [41] and
by regulating expression of tumor antigens via STAT3 [14].
Although not related to Wnt5a signaling, SFRP3 has been shown
to reverse EMT, decrease activity and expression of matrix
metalloproteases and decrease activation of b-catenin in other
types of cancer [36,37].
In summary, our data reveal that SFRP3 expression is down-
regulated in malignant melanoma tissue and melanoma cells and
can be restored in malignant melanoma cell lines following
demethylation of the SFRP3 gene. Functionally, addition of
Figure 2. Methylation of SFRP3 in melanoma cell lines. A, Schematic representation of the promoter region together with the first exon of the
SFRP3 gene. The CpG rich areas and the site of the methylation specific PCR primer are indicated. B, Methylation specific PCR. Hermes 3A, A375,
A2058 and HTB63 cells were treated for 72 h with 5 mM5 9AZA and analyzed using methylation specific PCR. Universally unmethylated DNA (UM
DNA) and methylated DNA (M DNA) were used as negative and positive controls, respectively. The image is representative of at least 3 independent
experiments. C, SFRP3 mRNA expression after demethylation treatment. Hermes 3A, A375, A2058 and HTB63 cells were treated with 59AZA as in B
and relative mRNA expression of SFRP3 was analyzed using RT-QPCR. The graph is representative of data from 3 independent experiments and error
bars denote SD within one experiment. The relative expression of each cell line is normalized to the untreated control of the same cell line. D, SFRP3
protein levels in the media from the indicated cell lines after demethylation treatment. A375, A2058 and HTB63 cells were treated as described for B
and the SFRP3 protein content analyzed using the ELISA kit as described in Figure 1. The results are given as a percentage compared to non-
demethylated control cells. Error bars represent SEM (n=4). E, SFRP3 protein expression in the melanoma cell lines. The indicated melanoma cell lines
were analyzed for their SFRP3 content by fluorescence microscopy after demethylation treatment using non-treated cells as controls. Representative
immunofluorescence images from at least 3 independent experiments. *=p,0.05, **=p,0.01.
doi:10.1371/journal.pone.0018674.g002
Figure 3. Recombinant SFRP3 decreases migration and invasion of melanoma cells. A, Invasion assay using Matrigel invasion chambers.
A2058 cells were resuspended in serum free media and treated in the upper chamber with 1 mg/ml of rSFRP3 or carrier (0.1% BSA in PBS) and allowed
to invade for 24 h. The error bars represent SEM, (n=5). B, Wound healing assay. A2058 cells were treated with either 1 mg/ml of rSFRP3 (dashed line,
squares) or carrier (full line, circles). Pictures were taken of the scratches at 0, 16, 24 and 48 h. Data is given as percentage of wound area closed at
each time point. The error bars represent SEM, (n=5). C, Migration assay, A2058 cells were treated with either 1 mg/ml of rSFRP3 or carrier in serum-
free media and migration of non-dividing individual cells was analyzed manually by tracking the speed of cells for 12 h. The error bars represent SEM,
(n=5). *=p,0.05. D, Wnt5a protein expression analysis. Wnt5a expression was analyzed in A2058 cells and HTB63 cells using western blotting.
doi:10.1371/journal.pone.0018674.g003
SFRP3 and Wnt5a-Dependent Melanoma Cell Migration
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This effect is readily explained by SFRP3-induced inhibition of
Wnt5a signaling. These data suggest that SFRP3 acts as a
metastasis suppressor in malignant melanoma.
Materials and Methods
Cell culture
All melanoma cell lines were grown in 5% CO2 at 37uCi na
humidified atmosphere. The malignant melanoma cells A375,
A2058 and HTB63 were obtained from the American Type
Culture Collection (ATCC Manassas, VA) and grown according
to their recommendations. Hermes 3A cells were kindly provided
by Professor Dorothy C Bennett, Division of Biomedical Sciences,
St. George’s, University of London, UK and grown according to
their instructions. In brief, Hermes 3A cells were grown in 10%
CO2 in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 10
5 U/L penicillin, 100 mg/L streptomycin, 2 mM
glutamine, 7.5 mg/ml phenol red, 200 nM TPA, 200 pM Cholera
toxin, 10 nM Endothelin-1, and human stemcell factor, 10 ng/ml
Figure 4. SFRP3 can inhibit Wnt5a signaling. A, Topflash reporter assay. A2058 cells transiently transfected with Topflash and Fopflash plasmids.
Where appropriate, cells were pre-treated with 1 mg/ml rSFRP3 or carrier, and after 24 h cells were treated with the indicated combinations of Wnt
ligands (0.2 mg/ml rWnt5a and 0.05 mg/ml rWnt3a) as indicated for an additional 24 h. The image is representative of 5 independent experiments and
the error bars represent SD within one experiment. B, Measurement of intracellular Ca
2+ signaling. rWnt5a (0.1 mg/ml, addition indicated by arrows)
was added to A2058 cells pre-treated with carrier (upper panel) or 1 mg/ml rSFRP3 (lower panel). Traces are representative images of 4 separate
experiments. C, DCa
2+ ratio values from A2058 cells pre-treated with either carrier or 1 mg/ml rSFRP3 and then stimulated with 0.1 mg/ml rWnt5a.
Error bars represent SD (n=4). **=p,0,01.
doi:10.1371/journal.pone.0018674.g004
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analyzed for the absence of mycoplasma contamination. All
reagents were of analytical grade and purchased from Sigma-
Aldrich (St Louis, MO) unless otherwise noted.
RNA extraction, RT-PCR and QPCR
RNA was extracted according to the manufacturer’s instruc-
tions using the RNeasy Plus kit (Qiagen Hilden, Germany). 1 mgo f
RNA was used for cDNA synthesis using random primers and M-
MuLV reverse transcriptase. PCR was performed using 16 of
106Taq Buffer with KCl, 1.5 mM MgCl, 0.2 mM dNTPs,
0.4 mM primers, 1 unit Taq DNA polymerase enzyme and 1–
3 ml cDNA in 25 ml reactions for 30 cycles. PCR products were
separated on 2% agarose gels and visualized using GelRed on a
UV board. QPCR was performed with Maxima SYBR Green
QPCR master mix in 25 ml reactions with 100 nM primers for 40
cycles. The housekeeping genes, UBC, SDHA and YWHAZ were
used as internal controls [42] for the reactions with specific
primers (all primer sequences are listed in Table 1). All PCR
products were obtained from Fermentas (Burlington, Ontario,
Canada).
Treatment with demethylating drugs, DNA extraction,
bisulphate treatment and methylation specific PCR
Cells were treated in 10 cm plates with 5 mM5 9Aza-
deoxycytidine, (59AZA) for 72 h with medium and the drug
replaced every 24 h. DNA was extracted according to the
manufacturer’s instructions using the DNA Blood and Tissue
Kit (Qiagen). 0.5 mg of DNA was used for bisulphate treatment
using the Epitect bisulphate kit (Qiagen) according to the
manufacturer’s instructions. Universally unmethylated and meth-
ylated DNA were used as positive and negative controls
respectively for methylation specific PCR (EpiTect Control DNAs,
Qiagen). Methylation specific PCR reactions were carried out as
described above (all primer sequences are listed in Table 1). CpG
analysis was carried out using the UCSC Genome Browser
Figure 5. SFRP3 inhibits migration in melanoma cells by antagonizing Wnt5a. A, Migration assay using Wnt5a knockdown cells. siRNA
transfected A2058 cells were grown in serum-free media for 24 h and then treated with 1 mg/ml rSFRP3 or carrier. Migration was analyzed using time-
lapse microscopy for 24 h. The error bars represent SD, (n=4). B, Wnt5a knockdown. The knockdown of Wnt5a in A2058 cells were analyzed using
western blot but also by RT-PCR (Figure S4). C, Migration assay using rWnt5a and rSFRP3 in A2058 cells. Cells were pre-treated with either carrier or
1 mg/ml rSFRP3 in serum-free media for 24 h. The cells were then treated with rWnt5a 0.2 mg/ml and analyzed using time-lapse microscopy as in A for
24 h. The error bars represent SD, (n=4). D, SFRP3 conditioned medium and migration assay. HTB63 cells were transfected with pCMV6-Empty-Vector
or pCMV6-SFRP3 and kept in serum-free media for 24 h. These media were transferred to non-transfected HTB63 cells that were then analyzed using
time-lapse microscopy as in A. Error bars represent SD (n=3). *=p,0.05.
doi:10.1371/journal.pone.0018674.g005
SFRP3 and Wnt5a-Dependent Melanoma Cell Migration
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PCR primers were designed using MethPrimer (http://www.
urogene.org/methprimer).
Wound healing
For wound healing experiments the cells were seeded in 35 mm
plates and grown to confluency. After 24 h serum starvation, three
scratches were made in each plate using a 200 ml pipette tip. Cells
were then treated with carrier (0.1% BSA in PBS) or 1 mg/ml
rSFRP3 (R & D Systems). Pictures of the scratches were taken at
the time points indicated. Sizes of the scratches were measured
using the Image-J software.
Time-lapse microscopy
The time-lapse migration experiments were performed using
cells seeded at 40–50% confluency. The cells were serum starved
for 24 h and treated with either carrier (0.1% BSA in PBS), 1 mg/
ml rSFRP3 or 0.2 mg/ml rWnt5a as indicated. Pictures were taken
every 5–15 min over a 12 h period in a humidified 37uC chamber
with 5% CO2. The speed of migration of non-dividing individual
cells was traced manually using the Volocity software (PerkinEl-
mer, Waltham, MA).
Matrigel invasion assays
Matrigel invasion chambers (BD Franklin Lakes, NJ) with 8 mm
pore sizes in a 24-well plate format were used. After 24 h serum
starvation, A2058 cells were resuspended in serum free media and
1 mg/ml of rSFRP3 or carrier (0.1% BSA in PBS) was added to
the upper chamber. 10% serum containing medium was added to
the lower chamber. The cells were allowed to invade for 24 h. The
membranes were wiped to remove the matrigel and fixed with 4%
paraformaldehyde, stained with crystal violet and the number of
cells that had invaded through to the other side of the membrane
were counted.
Antibodies, immunofluorescence and western blot
For western blotting, cells were lysed in Triton lysis buffer
(50 mM Tris (pH 7,5), 1% Triton- X100, 140 mM NaCl, 0.5 mM
EDTA, 0.5 mM MgCl2, 10 mM NaF, 2 mM Na3VO4, 1 mM
Pefabloc and 1 mg/ml Leupeptin). 30–50 mg of protein was
separated on SDS-polyacrylamide gels and transferred to PVDF
membranes. Membranes were incubated with primary anti-Wnt5a
antibody (1:1000) produced as previously described [43]. a-tubulin
and b-actin were used as loading controls (antibodies from Santa
Cruz Biotechnology, Santa Cruz, CA). Visualization was done
using Bio-Rad XRS+ and Image Lab software (BioRad Hercules,
CA). For immunofluorescence cells were grown on glass slides and
fixed using PBS with 5% formaldehyde, 2% sucrose. Cells were
then permeabilized with 0.5% NP40, 10% sucrose and 1% calf
serum and blocked for 30 min with 10% goat serum in 0.02%
Tween in PBS. Cells were incubated for 1 h with SFRP3
monoclonal antibody (R&D systems 1:100) and then with
Alexafluor488 secondary antibody (1:500) for 1 h and counter-
stained with DAPI (Invitrogen). The intensity of entire immuno-
fluorescence images was measured using the Image J software and
expressed as Alexa 488/DAPI ratio.
SFRP3 ELISA
The levels of secreted SFRP3 from the different cell lines were
analyzed using a commercial sandwich ELISA kit (R&D Research
Minneapolis, MN). The ELISA was performed according to the
manufacturer’s instructions. Briefly, cells were grown in serum free
media for 48 hours or for 24 hours after 59aza treatment before
the medium was removed. It was then concentrated using 10 kDa
concentration columns (Millipore Billerica, MA) and subsequently
analyzed using the ELISA kit. The SFRP3 levels were normalized
against total protein.
Transient transfections
For siRNA transfections, A2058 cells were transfected with
30 nM of siRNA against Wnt5a or scrambled control siRNA
(Applied Biosystems, Carlsbad, CA). HTB63 cells were transfected
with pCMV6-AC-GFP or pCMV6-AC-GFP-FrzB (RefSeq
NM_001463, Origene, Rockville, MD) using Lipofectamine2000
(Invitrogen) transfection reagent at a ratio of 1:2. For transfections,
cells were incubated in transfection mix for 4–6 h, then kept in
normal media overnight and then changed into serum-free media
for 24 h. For the Topflash assay, A2058 cells were transfected with
Topflash (Addgene plasmid 12456, TCF/Lef driven luciferase
construct) or Fopflash plasmids (Addgene plasmid 12457, Inverted
TCF/Lef driven luciferase construct) and with Renilla luciferase
plasmid [44].
Luciferase reporter assay
Transfected A2058 cells were kept in serum-free media with
1 mg/ml rSFRP3 or carrier for 24 h. After this time the cells were
treated with carrier, 0.05 mg/ml rWnt3a or 0.2 mg/ml rWnt5a for
24 h in the combinations indicated in Figure 4A. Luciferase
activity was analyzed according to the manufacturer’s instructions
using a Dual Luciferase reporter assay (Promega Madison, WI).
Luciferase activity was normalized against Renilla activity. Cells
were treated in duplicates and each lysate was analyzed twice.
Measurement of calcium signaling
Determination of cytosolic free calcium levels was carried out in
A2058 cells that had been pre-incubated with carrier (0.1%BSA in
PBS) or 1 mg/ml rSFRP3 for 24 h before the experiment. The
cells were then incubated in 4 mM fura-2/AM for 30 min, after
which they were washed and placed in a chamber containing a
physiologically balanced calcium medium (136 mM NaCl,
4.7 mM KCl, 1.2 mM MgSO4, 1.1 mM CaCl2, 1.2 mM
KH2PO4, 5 mM NaHCO3, 5.5 mM glucose, 20 mM HEPES)
at 37uC. Fluorescent signals of cells were recorded before and after
stimulation with rWnt-5a (0.1 mg/ml) using excitation wavelengths
of 340 and 380 nm and an emission wavelength of 510 nm. For
Table 1. Primer sequences.
Primer sequence Primer name
GTTGTTGTTTCGAAGGTTAGAC Left Meth primer
AATAAAACAAAATACAACCGCG Right Meth primer
TCAGGACCACATGCAGTA Wnt5a F
CTCATGGCGTTCACCACC Wnt5a R
TCCGGAAATAGGTCTTCTGTGT SFRP 3 F
CGGAGCTGATTTTCCTATGG SFRP 3 R
ATTTGGGTCGCGGTTCTTG UBC F
TGCCTTGACATTCTCGATGGT UBC R
ACTTTTGGTACATTGTGGCTTCAA YWHAZ F
CCGCCAGGACAAACCAGTAT YWHAZ R
TGGGAACAAGAGGGCATCTG SDHA F
CCACCACTGCATCAAATTCATG SDHA R
doi:10.1371/journal.pone.0018674.t001
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field of vision was monitored, after which the calcium response of
at least 10 single cells was calculated as the change in fluorescence
intensity ratio (340/380 nm). The Ca
2+ traces shown are
representative of 4 separate experiments. The accumulated results
of the induced Ca
2+ signals are represented as DCa
2+ (D Ratio
340/380 in the figures).
Proliferation assay
2–5000 cells were seeded in 96 well plates. Cells were kept in
serum-free medium for 24 h and then treated with 1 mg/ml
rSFRP3 or carrier for 24 or 48 h. At the end of the experiment
10 mlo f1 6WST1 reagent (Roche, Basel Switzerland) was added
in 100 ul of medium. Cells were incubated for 2 h at 37uC and
absorbance was then measured at 420 nm with 600 nm as
reference wavelength.
Statistical analysis
Means, standard deviations and standard error of the means
were calculated and plotted using GraphPad Prism 5. In Figure 1A
and B the unpaired Student’s t-test was used, while in Figure 1D
and 2D the Mann-Whitney test was used. In Figures 3 and 4
paired Student’s t-test was used. All experiments were carried out
at least three times for experiments where the Student’s t-test was
used and at least 4 times for experiments where the Mann-
Whitney test was used.
Supporting Information
Figure S1 Fluorescence intensity measurement of basal
SFRP3 protein expression in cell lines. Melanocytes and
melanoma cells were analyzed for SFRP3 expression using
immunofluorescence that was quantified by measuring the
intensity from at least 6 images from each of 3 separate
experiments. The data are given as Arbitrary Units (AU).
*=p,0.05, **=p,0.01.
(PDF)
Figure S2 Fluorescence intensity measurement of
SFRP3 protein expression after demethylation treat-
ment. Melanoma cells treated with 59aza were analyzed for
SFRP3 expression using immunofluorescence that was quantified
by measuring the intensity from at least 6 images from each of 3
separate experiments. The data are given as Arbitrary Units (AU).
*=p,0.05.
(PDF)
Figure S3 Analysis of rSFRP3 on melanoma cell viabil-
ity. Malignant melanoma cell lines were kept in serum free media
for 24 h and then treated with 1 mg/ml rSFRP3 or carrier to
investigate the difference in cell viability using a WST assay. A,
A2058 cells treated for 24 h. B, A2058 cells treated for 48 h. The
error bars represent SD (n=3).
(PDF)
Figure S4 QPCR analysis of Wnt5a knockdown by
siRNA. Wnt5a was knocked down in A2058 cells and then
analyzed by QPCR. Wnt5a expression was normalized against the
housekeeping genes YWHAZ, UBC and SDHA and is expressed
as relative expression compared to Scrambled siRNA control.
(PDF)
Figure S5 Analysis of SFRP3 over-expression. HTB63
cells were transfected with pCMV6- AC-GFP or pCMV6-AC-
GFP-FrzB (Origene) and kept in serum-free media for 24 h.
Expression was analyzed using quantitative RT-PCR.
(PDF)
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